{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:30:35Z","timestamp":1788838235509,"version":"build-2803163510"},"reference-count":79,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Romanian Ministry of Research and Innovation","award":["CNFISFDI-2021-0300"],"award-info":[{"award-number":["CNFISFDI-2021-0300"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>(1) Background: Parkinson\u2019s disease and arterial hypertension are likely to coexist in the elderly, with possible bidirectional interactions. We aimed to assess the role of antihypertensive agents in PD emergence and\/or progression. (2) We performed a systematic search on the PubMed database. Studies enrolling patients with Parkinson\u2019s disease who underwent treatment with drugs pertaining to one of the major antihypertensive drug classes (\u03b2-blockers, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium-channel blockers) prior to or after the diagnosis of parkinsonism were scrutinized. We divided the outcome into two categories: neuroprotective and disease-modifying effect. (3) We included 20 studies in the qualitative synthesis, out of which the majority were observational studies, with only one randomized controlled trial. There are conflicting results regarding the effect of antihypertensive drugs on Parkinson\u2019s disease pathogenesis, mainly because of heterogeneous protocols and population. (4) Conclusions: There is low quality evidence that antihypertensive agents might be potential therapeutic targets in Parkinson\u2019s disease, but this hypothesis needs further testing.<\/jats:p>","DOI":"10.3390\/biomedicines10030653","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T12:58:36Z","timestamp":1647003516000},"page":"653","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Shared Molecular Targets in Parkinson\u2019s Disease and Arterial Hypertension: A Systematic Review"],"prefix":"10.3390","volume":"10","author":[{"given":"Delia","family":"Tulb\u0103","sequence":"first","affiliation":[{"name":"Department of Neurology, Colentina Clinical Hospital, 020125 Bucharest, Romania"},{"name":"Department of Clinical Neurosciences, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Colentina\u2013Research and Development Center, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mioara","family":"Avasilichioaei","sequence":"additional","affiliation":[{"name":"Department of Neurology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Dima","sequence":"additional","affiliation":[{"name":"Department of Neurology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cr\u0103ciun","sequence":"additional","affiliation":[{"name":"Department of Neurology, Colentina Clinical Hospital, 020125 Bucharest, Romania"},{"name":"Colentina\u2013Research and Development Center, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"B\u0103l\u0103nescu","sequence":"additional","affiliation":[{"name":"Colentina\u2013Research and Development Center, Colentina Clinical Hospital, 020125 Bucharest, Romania"},{"name":"Clinical Research Unit, RECIF (R\u00e9seau d\u2019Epid\u00e9miologie Clinique International Francophone), 020125 Bucharest, Romania"},{"name":"Department of Internal Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-9149","authenticated-orcid":false,"given":"Adrian","family":"Buzea","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Cardiology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7954-0098","authenticated-orcid":false,"given":"Cristian","family":"B\u0103icu\u0219","sequence":"additional","affiliation":[{"name":"Colentina\u2013Research and Development Center, Colentina Clinical Hospital, 020125 Bucharest, Romania"},{"name":"Department of Internal Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Internal Medicine, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4826-2598","authenticated-orcid":false,"given":"Bogdan","family":"Popescu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Colentina Clinical Hospital, 020125 Bucharest, Romania"},{"name":"Department of Clinical Neurosciences, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Laboratory of Cell Biology, Neurosciences and Experimental Myology, \u201cVictor Babe\u0219\u201d National Institute of Pathology, 050096 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2019.08.002","article-title":"Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology","volume":"36","author":"Simon","year":"2020","journal-title":"Clin. Geriatr. Med."},{"key":"ref_2","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators (2018). Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol., 17, 939\u2013953."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1176\/jnp.14.2.223","article-title":"An essay on the shaking palsy 1817","volume":"14","author":"Parkinson","year":"2002","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00701-008-1619-5","article-title":"Noradrenergic modulation of subthalamic nucleus activity in human: Metoprolol reduces spiking activity in microelectrode recordings during deep brain stimulation surgery for Parkinson\u2019s disease","volume":"150","author":"Coenen","year":"2008","journal-title":"Acta Neurochir."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(19)30400-4","article-title":"Beta-Adrenoreceptors and the risk of Parkinson\u2019s disease","volume":"19","author":"Hopfner","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.neuint.2010.03.019","article-title":"Adrenoceptors in brain: Cellular gene expression and effects on astrocytic metabolism and [Ca(2+)] i","volume":"57","author":"Hertz","year":"2010","journal-title":"Neurochem. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"Beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson\u2019s disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ijbiomac.2019.10.137","article-title":"Unravelling the inhibitory and cytoprotective potential of diuretics towards amyloid fibrillation","volume":"150","author":"Malik","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_9","first-page":"5922","article-title":"Indapamide suppresses amyloid-\u03b2 production in cellular models of Alzheimer\u2019s disease through regulating BACE1 activity","volume":"10","author":"Lu","year":"2017","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jalz.2011.03.010","article-title":"Diuretic use is associated with better learning and memory in older adults in the Ginkgo Evaluation of Memory Study","volume":"8","author":"Yasar","year":"2012","journal-title":"Alzheimer Dement."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"17579","DOI":"10.1074\/jbc.M112.434787","article-title":"A blood-brain barrier (BBB) disrupter is also a potent alpha-synuclein (alpha-syn) aggregation inhibitor: A novel dual mechanism of mannitol for the treatment of Parkinson disease (PD)","volume":"288","author":"Rockenstein","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ye, Q., Zhang, Z., Zhang, W., Ding, Y., Zhao, F., Zhang, J., and Song, Y. (2020). Investigation of the Selectivity of L-Type Voltage-Gated Calcium Channels 1.3 for Pyrimidine-2,4,6-Triones Derivatives Based on Molecular Dynamics Simulation. Molecules, 25.","DOI":"10.3390\/molecules25225440"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nature05865","article-title":"\u2018Rejuvenation\u2019 protects neurons in mouse models of Parkinson\u2019s disease","volume":"447","author":"Chan","year":"2007","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1085\/jgp.200709946","article-title":"Ion channels as drug targets: The next GPCRs","volume":"131","author":"Kaczorowski","year":"2008","journal-title":"J. Gen. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1021\/jm301839q","article-title":"Ligand based approach to L-type calcium channel by imidazo [2,1-b]thiazole-1,4-dihydropyridines: From heart activity to brain affinity","volume":"56","author":"Locatelli","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1085\/jgp.200910308","article-title":"Molecular endpoints of Ca2+\/calmodulin-and voltage-dependent inactivation of Ca(v)1.3 channels","volume":"135","author":"Tadross","year":"2010","journal-title":"J. Gen. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2174\/0929867311320100005","article-title":"Ion channels as drug targets in central nervous system disorders","volume":"20","author":"Waszkielewicz","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/sctm.18-0180","article-title":"Stimulation of L-type calcium channels increases tyrosine hydroxylase and dopamine in ventral midbrain cells induced from somatic cells","volume":"9","author":"Jefri","year":"2020","journal-title":"Stem Cells Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2217\/nnm-2016-0267","article-title":"Combining nanoscale magnetic nimodipine liposomes with magnetic resonance image for Parkinson\u2019s disease targeting therapy","volume":"12","author":"Ji","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/s41467-019-09494-2","article-title":"Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing","volume":"10","author":"Siddiqi","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0024-3205(97)00881-3","article-title":"Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists","volume":"61","author":"Uchida","year":"1997","journal-title":"Life Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s10072-018-3662-1","article-title":"L-type calcium channel blockers and a symptom complex mimicking de Melo-Souza\u2019s syndrome","volume":"40","author":"Kaur","year":"2019","journal-title":"Neurol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jackson, L., Eldahshan, W., Fagan, S.C., and Ergul, A. (2018). Within the Brain: The Renin Angiotensin System. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030876"},{"key":"ref_24","unstructured":"Kandel, E.R., Schwartz, J.H., Jessell, T.M., Siegelbaum, S.A., Hudspeth, A.J., and Mack, S. (2013). Principles of Neural Science, McGraw-Hill Education LLC."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.sjbs.2020.01.026","article-title":"Role of brain renin angiotensin system in neurodegeneration: An update","volume":"27","author":"Abiodun","year":"2020","journal-title":"Saudi. J. Biol. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1470320309347789","article-title":"The role of the central renin-angiotensin system in Parkinson\u2019s disease","volume":"11","author":"Mertens","year":"2010","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.phrs.2017.06.017","article-title":"Beneficial effects of Angiotensin II receptor blockers in brain disorders","volume":"125","author":"Saavedra","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1038\/sj.jhh.1001442","article-title":"The renin-angiotensin system in the brain: Possible therapeutic implications for AT(1)-receptor blockers","volume":"16","author":"Culman","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/mds.25614","article-title":"Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson\u2019s disease","volume":"28","author":"Valenzuela","year":"2013","journal-title":"Mov. Disord."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1042\/CS20180189","article-title":"The depressor axis of the renin-angiotensin system and brain disorders: A translational approach","volume":"132","author":"Gironacci","year":"2018","journal-title":"Clin. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: A clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","article-title":"Drug-induced parkinsonism","volume":"8","author":"Shin","year":"2012","journal-title":"J. Clin. Neurol."},{"key":"ref_35","first-page":"215","article-title":"Drug-induced Parkinson\u2019s disease. A clinical review","volume":"18","author":"Bohlega","year":"2013","journal-title":"Neurosciences"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1212\/WNL.0000000000007694","article-title":"Use of beta2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease","volume":"93","author":"Hopfner","year":"2019","journal-title":"Neurology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40261-019-00771-y","article-title":"Chronic Use of beta-Blockers and the Risk of Parkinson\u2019s Disease","volume":"39","author":"Koren","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ana.25341","article-title":"Beta2-adrenoreceptor medications and risk of Parkinson disease","volume":"84","author":"Gross","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/mds.108","article-title":"Beta2-adrenoceptor agonists and antagonists and risk of Parkinson\u2019s disease","volume":"33","author":"Gronich","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.wnl.0000303818.38960.44","article-title":"Use of antihypertensives and the risk of Parkinson disease","volume":"70","author":"Becker","year":"2008","journal-title":"Neurology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5414\/CP203559","article-title":"The association between antihypertensive therapy and the incidence of Parkinson\u2019s disease in patients followed in general practices in Germany","volume":"57","author":"Warda","year":"2019","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40263-020-00736-2","article-title":"Beta-Adrenoceptor Drugs and Parkinson\u2019s Disease: A Nationwide Nested Case-Control Study","volume":"34","author":"Conte","year":"2020","journal-title":"CNS Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.21937","article-title":"L-type calcium channel blockers and Parkinson disease in Denmark","volume":"67","author":"Ritz","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.parkreldis.2006.08.011","article-title":"Calcium channel blockers and beta-blockers in relation to Parkinson\u2019s disease","volume":"13","author":"Ton","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/aje\/kwaa012","article-title":"Beta 2-Agonists and the Incidence of Parkinson Disease","volume":"189","author":"Giorgianni","year":"2020","journal-title":"Am. J. Epidemiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.gaitpost.2017.02.007","article-title":"Use of ACE-inhibitors and falls in patients with Parkinson\u2019s disease","volume":"54","author":"Laudisio","year":"2017","journal-title":"Gait Posture"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/mds.21579","article-title":"Worsening of motor symptoms and gynecomastia during spironolactone treatment in a patient with Parkinson\u2019s disease and congestive heart failure","volume":"22","author":"Teive","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/WNF.0000000000000114","article-title":"Bumetanide to Treat Parkinson Disease: A Report of 4 Cases","volume":"39","author":"Damier","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lee, Y.C., Lin, C.-H., Wu, R.-M., Lin, J.-W., Chang, C.-H., and Lai, M.-S. (2014). Antihypertensive agents and risk of Parkinson\u2019s disease: A nationwide cohort study. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098961"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000235641","article-title":"Antihypertensive agents and risk of Parkinson\u2019s disease, essential tremor and dementia: A population-based prospective study (NEDICES)","volume":"33","author":"Louis","year":"2009","journal-title":"Neuroepidemiology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","article-title":"The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson\u2019s disease","volume":"30","author":"Reardon","year":"2000","journal-title":"Aust. N. Z. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"117412","DOI":"10.1016\/j.jns.2021.117412","article-title":"Calcium Channel blockers are associated with reduced risk of Parkinson\u2019s disease in patients with hypertension: A population-based retrospective cohort study","volume":"424","author":"Tseng","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/aje\/kwr362","article-title":"Use of calcium channel blockers and Parkinson\u2019s disease","volume":"175","author":"Pasternak","year":"2012","journal-title":"Am. J. Epidemiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/mds.23191","article-title":"Calcium channel blocker use and risk of Parkinson\u2019s disease","volume":"25","author":"Simon","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group STEADY-PD III Investigators (2020). Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Ann. Intern. Med., 172, 591\u2013598.","DOI":"10.7326\/M19-2534"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ana.22616","article-title":"Dihydropyridine calcium channel blockers and the progression of parkinsonism","volume":"71","author":"Marras","year":"2012","journal-title":"Ann. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10048-011-0292-7","article-title":"Genetic variability in SNCA and Parkinson\u2019s disease","volume":"12","author":"Pihlstrom","year":"2011","journal-title":"Neurogenetics"},{"key":"ref_58","unstructured":"GeneCards (2021, July 30). The Human Gene Database; ADRB2 Gene. Available online: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=ADRB2."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/1533317513488919","article-title":"The role of beta-adrenergic blockers in Parkinson\u2019s disease: Possible genetic and cell-signaling mechanisms","volume":"28","author":"Luong","year":"2013","journal-title":"Am. J. Alzheimer Dis. Demen."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2217\/bmm.10.94","article-title":"Urate: A novel biomarker of Parkinson\u2019s disease risk, diagnosis and prognosis","volume":"4","author":"Cipriani","year":"2010","journal-title":"Biomark. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bcp.2018.12.007","article-title":"A new human pyridinium metabolite of furosemide, inhibitor of mitochondrial complex I, is a candidate inducer of neurodegeneration","volume":"160","author":"Laurence","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41467-018-03802-y","article-title":"GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease","volume":"9","author":"Lozovaya","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s13311-018-0646-z","article-title":"Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death","volume":"15","author":"Sucunza","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","article-title":"Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson\u2019s disease","volume":"26","author":"Toblli","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/pds.3781","article-title":"Calcium channel blocker use and risk of Parkinson\u2019s disease: A meta-analysis","volume":"24","author":"Lang","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1172\/JCI95898","article-title":"Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress","volume":"128","author":"Guzman","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/nn.3717","article-title":"Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase","volume":"17","author":"Guzman","year":"2014","journal-title":"Nat. Neurosci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nature09536","article-title":"Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1","volume":"468","author":"Guzman","year":"2010","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jchemneu.2018.02.001","article-title":"Nimodipine attenuates the parkinsonian neurotoxin, MPTP-induced changes in the calcium binding proteins, calpain and calbindin","volume":"95","author":"Singh","year":"2019","journal-title":"J. Chem. Neuroanat."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e21989","DOI":"10.7554\/eLife.21989","article-title":"Cooperative and acute inhibition by multiple C-terminal motifs of L-type Ca(2+) channels","volume":"6","author":"Liu","year":"2017","journal-title":"eLife"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40263-016-0393-9","article-title":"Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson\u2019s Disease: Therapeutic Rationale and Current Status","volume":"30","author":"Swart","year":"2016","journal-title":"CNS Drugs"},{"key":"ref_72","first-page":"697404","article-title":"Reduced Risk of Parkinson\u2019s Disease in Users of Calcium Channel Blockers: A Meta-Analysis","volume":"2015","author":"Gudala","year":"2015","journal-title":"Int. J. Chronic Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2015.5","article-title":"Targeting voltage-gated calcium channels in neurological and psychiatric diseases","volume":"15","author":"Zamponi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/pr.114.009654","article-title":"The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential","volume":"67","author":"Zamponi","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuron.2009.01.033","article-title":"Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons","volume":"62","author":"Mosharov","year":"2009","journal-title":"Neuron"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","article-title":"Transneuronal Propagation of Pathologic alpha-Synuclein from the Gut to the Brain Models Parkinson\u2019s Disease","volume":"103","author":"Kim","year":"2019","journal-title":"Neuron"},{"key":"ref_77","first-page":"CD008535","article-title":"Anti-hypertensive drugs as disease-modifying agents for Parkinson\u2019s disease: Evidence from observational studies and clinical trials","volume":"11","author":"Rees","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_78","first-page":"82","article-title":"GRADE system: Classification of quality of evidence and strength of recommendation","volume":"92","year":"2014","journal-title":"Cir. Esp."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1016\/S1353-8020(13)70032-4","article-title":"Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson\u2019s disease","volume":"20","author":"Youdim","year":"2014","journal-title":"Parkinsonism. Relat. Disord."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/3\/653\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:35:09Z","timestamp":1760135709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/3\/653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":79,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["biomedicines10030653"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10030653","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]}}}